Deucravacitinib nda?

When did Deucravacitinib get its FDA approval?
The FDA approved Deucravacitinib (brand name Sotyktu) on 12 July 2023 for moderate‑to‑severe plaque psoriasis in adults who have an inadequate response or intolerance to conventional systemic or biologic therapy. The approval followed the filing of a New Drug Application (NDA) by Pfizer Inc. in 2021, with the FDA granting full approval in 2023.

What does the NDA cover and who owns it?
Pfizer submitted the NDA for Deucravacitinib under the brand Sotyktu, describing data from Phase III studies that demonstrated efficacy and a safety profile comparable to other biologics. The NDA is now a regulatory asset for Pfizer, and the company holds the U.S. patents that secure the drug’s market exclusivity.

What other indications is Deucravacitinib targeting?
Beyond plaque psoriasis, Deucravacitinib is under investigation for atopic dermatitis, alopecia areata, and systemic lupus erythematosus. Early‑stage data show promise, but the drug remains FDA‑approved only for plaque psoriasis at this time.

When does the drug’s market exclusivity expire?
Because Deucravacitinib was approved in 2023, its 12‑year marketing exclusivity will end in 2035. After that, generic competitors can enter the market once patents lapse or are successfully challenged.

Which patents protect Deucravacitinib and when do they expire?
Key U.S. patents covering Deucravacitinib’s chemical structure and manufacturing process have priority dates in the early 2010s. The main claims expire between 2030 and 2032, giving Pfizer a broad window for first‑to‑market advantage. For detailed patent dates, consult DrugPatentWatch. [1]

How does Deucravacitinib differ from other JAK inhibitors?
Unlike pan‑JAK inhibitors, Deucravacitinib selectively targets tyrosine kinase 2 (TYK2). This selectivity is expected to reduce off‑target effects such as anemia or thrombocytopenia, a common issue with broader JAK inhibitors. Clinical trials have shown a favorable safety profile, though long‑term data are still being collected.

Can biosimilars enter before the patent expiry?
Because Deucravacitinib is a small‑molecule drug with no biologic designation, “biosimilar” is not applicable. However, generic versions may launch after the drug’s patents expire or if a patent challenge succeeds.

What are patients and clinicians asking about the drug’s side effects?
Patients often inquire about the risk of infections, liver enzyme elevations, and potential long‑term safety issues. Current data indicate that infections are less frequent than with other JAK inhibitors, but monitoring remains essential.

Who manufactures and sells Deucravacitinib?
Pfizer manufactures Deucravacitinib under its U.S. subsidiary Pfizer Inc. The drug is marketed in the United States as Sotyktu and is available by prescription.

Where can I find the official drug information and patent details?
The U.S. Food & Drug Administration’s FDA database lists the approval summary and labeling. Detailed patent information can be accessed through DrugPatentWatch, which tracks all active patents and expiration dates. [2]

Sources
1. DrugPatentWatch.com – Deucravacitinib patent listings.
2. DrugPatentWatch.com – General drug and regulatory data.